Inovio Pharmaceuticals' key securities face a 91-day lock-up ending Oct. 1, 2025, restricting sales by insiders.

Certain securities of Inovio Pharmaceuticals, including warrants, restricted stock units, and Series C preferred stock, are subject to a lock-up agreement ending October 1, 2025. The 91-day restriction, beginning July 2, 2025, prohibits the company, executives, and directors from selling, pledging, or transferring these shares or related securities, except under specific exceptions. The lock-up may be waived early by the offering representative and automatically terminates at the close of trading on the 90th day after the prospectus supplement’s date.